Home > Haematology > ASH 2019 > Inclusive Medicine > CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

Presented By
Dr Karl Kilgore, Avalere, USA
Conference
ASH 2019
In a first-of-a-kind study using 2 years of Medicare claims data for chimaeric antigen receptor (CAR) T-cell therapies in patients aged ≥60 years with non-Hodgkin’s lymphoma, researchers have found clear evidence that this population derives more clinical benefit from this treatment compared with other patients who did not receive CAR T cells. Dr Karl M. Kilgore (Avalere, a healthcare consulting firm in Washington DC, USA) reported on 207 CAR T-cell recipients receiving Medicare (median age 71 years; 60% men; 87% Caucasian) [1]. In mid-2017, the 2 different CD19-directed CAR T-cell therapies tisagenlecleucel and axicabtagene ciloleucel were approved for the treatment of patients with relapsed or refractory large B-cell lymphoma who had already had ≥2 prior systemic therapies. The first claims came in October 2017, and the current study followed patients receiving either of these CAR T products until 30 September 2018. “This study provides the first real-wo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on